{"ticker": {"uuid": "a577e708-6fa2-48c8-a64c-cb99e126c4f8", "symbol": "VRCA", "name": "Verrica Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Verrica Pharmaceuticals Signs Distribution Deal With Medomie for Molluscum Treatment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/verrica-pharmaceuticals-signs-distribution-deal-124247885.html", "source_name": "MT Newswires", "published_at": "2026-07-21T12:42:47+00:00", "published_display": "21 Jul 2026 12:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica grants Medomie exclusive rights for YCANTH in Israel By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOalE0dE9PVzJndkpDeEFKS1NOd1hiX3l5WEpRMWtaRVVwVVFvd1RuS2hqUElLZDNoa2NhSUgxbmgwcjZqS1dnTGJXbG5ncUZFRWphYm1ldldNSHRySUVZS2VsNnRYNW1CcHI2Q0s1SHFmdjQxSy1vUFg5NV9FVzFnMzhCUjhjT1BlRFlwamQzakVuSkFmMTA1U1l5UURPWVRCR2dHd0pqUFpfcFBtVHd3SHExVmh1azdiTlFUTkxn?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-21T12:15:51+00:00", "published_display": "21 Jul 2026 12:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica deal could bring YCANTH to Israeli children if approved", "summary": "Verrica Pharmaceuticals has signed an exclusive distribution, marketing, and supply agreement with Medomie Pharma to commercialize YCANTH for molluscum contagiosum in Israel. While Medomie will seek regulatory approval and distribute the product, Verrica will manufacture and supp", "url": "https://www.stocktitan.net/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-emk3bsvgo9zm.html", "source_name": "Stock Titan", "published_at": "2026-07-21T11:40:50", "published_display": "21 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 92, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH\u00ae for the Treatment of Molluscum Contagiosum in Israel", "summary": "Verrica Pharmaceuticals and Medomie Pharma have entered an exclusive distribution, marketing, and supply agreement to commercialize YCANTH\u00ae for molluscum contagiosum in Israel. Medomie will seek regulatory approval and distribute the product, while Verrica manufactures YCANTH and", "url": "https://www.manilatimes.net/2026/07/21/tmt-newswire/globenewswire/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-marketing-and-supply-agreement-to-commercialize-ycanth-for-the-treatment-of-molluscum-contagiosum-in-israel/2388404", "source_name": "The Manila Times", "published_at": "2026-07-21T11:40:50", "published_display": "21 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Verrica Pharmaceuticals (VRCA) Slides 4.13% as Resistance Holds Firm - Force Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPc2x3UDRDOUoxTGV2dTVfRFhVSEJNNE5uYlV5VU0yTWVQM1BYSFpsSTNQeHRXTnFhdGtaTVYxVm1FSk1Cb0Q2RUFETG1kSVVsRGNJMVpGNER0YWVmMkdDVUxQVVpsTWFtWGpucUNXYXlHRWloTjNOdW1Gd21nc094VmlBT0thMU8yMGZFQzlNSk8wUkd1X1pObTczSk12SXR5UHRBT3JvNHdab21Udnc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-11T07:00:00+00:00", "published_display": "11 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Slips 1.68% as Stock Tests Key Support Zone - Covered Call ETF", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPTEREZElhTFU3UGx2eUd4elhOZnl4Q3NaMjF0ZXFqdG5NQzI5OS1kS1Q1Ql9PSkxpQWZ5RXFRc1dYMlpBZ3JoVm5fZ1FSVTRDZERwWWFBY2thR0QxeERWNlo2Z3NIdC1IT3Y3Q0t1M1hraHBfSEFkMHI1b0U0bDFuM0ZjUnhwNi11V01MOUJXaXZ4R05DQ2VlbENNU1BXa0RjazI4TzRiOXRWYkU?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-10T16:41:06+00:00", "published_display": "10 Jul 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals (VRCA) Q1 2026 Earnings: EPS Miss Weighs on Shares Amid Ongoing Product Launch - Fiscal Year Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxObUVXU3NJdFJHYTNDazByejdtRmduOTVoNnpVR1NmWjMyeHdlX0xlYml0cW5BMC1VS0xXVk90eUliOUVnYzhKZUVYYzl6b2d5YzVaTXBxcjBEWFlqOEozTWdMRGZaclBGZkRoRzZYQUZoZXVESnZDUl8zb2NIT0VTQ3FWRlFEb0pjWGxWTG5kSURGc2FmelNjQ1AzMEpUa0s2eEZ5N2U0RzFZYjA4R080cXg1SVdNRDJyUEM3Zldhelp6QzhFRW5RazFVU09zX1lCTzNhQ0dJSGthaGdz?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-10T05:48:20+00:00", "published_display": "10 Jul 2026 05:48", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals holds the spotlight after recent market context", "summary": "Verrica Pharmaceuticals (VRCA) is highlighted for its Nasdaq listing and SEC reporting, with its commercial product YCANTH, a prescription treatment for molluscum contagiosum, being its primary revenue driver. Investors are encouraged to focus on the company's filings, investor m", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/verrica-pharmaceuticals-holds-the-spotlight-after-recent-market-context/69716519", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T18:10:34", "published_display": "07 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript", "summary": "Verrica Pharmaceuticals Inc. reported a 25.4% increase in U.S. Ycanth product revenue for Q1 2026, alongside the launch of Wycanth in Japan, signifying global expansion. The company is actively progressing its Phase III common warts program and achieved a strong gross product mar", "url": "https://www.gurufocus.com/stock/STU:1NE0/transcripts/8853242", "source_name": "GuruFocus", "published_at": "2026-07-05T09:11:56", "published_display": "05 Jul 2026 09:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRCA - Verrica Pharmaceuticals Inc Latest SEC Filings", "summary": "This article provides detailed financial and stock performance data for Verrica Pharmaceuticals Inc. (VRCA), including its latest market capitalization, income, sales, insider ownership, institutional ownership, and various profitability and growth metrics. It also lists the comp", "url": "https://finviz.com/stock?t=VRCA&p=d&b=2&ty=lf&page=17", "source_name": "Finviz", "published_at": "2026-07-04T09:09:38", "published_display": "04 Jul 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals (VRCA) Rises 2% as Shares Test Resistance Near $6.36 - Sentiment Shift", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQVGVzNU5lX1pZTmM2MUVCTVZOejMycnBkWUxhdS1iY2JmWXlOakRCSFZha1E5cDV1X1p6NnJHZVZobnJIeEVrZVBYZGsxdUNSRXZaNXRyeXFwVjdOdUdPdFFMcVVrZmpMdzVkRFVCMzN3SG5lWHpqNkwtX0g2SkN3SFF1aUtaOXBqSFE1V1ZSNVBuMWJBeE5VdG1nd2tQZFE3V1drQnh4NWFWMENwc2Z0Z2VJNA?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc.(NasdaqCM:VRCA) added to Russell Microcap Growth Benchmark Index", "summary": "Verrica Pharmaceuticals Inc. (NasdaqCM: VRCA) has been added to the Russell Microcap Growth Benchmark Index, which is based on Friday's closing market values. This inclusion indicates the company's strong growth potential and increased visibility within the financial markets. The", "url": "https://www.marketscreener.com/news/verrica-pharmaceuticals-inc-nasdaqcm-vrca-added-to-russell-microcap-growth-benchmark-index-ce7f5fddd981f126", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:39:29", "published_display": "29 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc.(NasdaqCM:VRCA) added to Russell 3000E Growth Benchmark", "summary": "Verrica Pharmaceuticals Inc. (NasdaqCM:VRCA) has been added to the Russell 3000E Growth Benchmark. The company specializes in dermatology therapeutics, developing and selling medications for skin diseases, with its commercial product YCANTH (VP-102) for molluscum contagiosum and ", "url": "https://www.marketscreener.com/news/verrica-pharmaceuticals-inc-nasdaqcm-vrca-added-to-russell-3000e-growth-benchmark-ce7f5fdedc80f426", "source_name": "marketscreener.com", "published_at": "2026-06-29T08:41:18", "published_display": "29 Jun 2026 08:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc.(NasdaqCM: VRCA) added to Russell Microcap Index", "summary": "Verrica Pharmaceuticals Inc. (NasdaqCM: VRCA) has been added to the Russell Microcap Index. The company is a dermatology therapeutics firm focused on developing and selling medications for skin diseases, with its primary product YCANTH (VP-102) approved for molluscum contagiosum ", "url": "https://www.marketscreener.com/news/verrica-pharmaceuticals-inc-nasdaqcm-vrca-added-to-russell-microcap-index-ce7f5fdeda80f120", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:39:34", "published_display": "29 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings ratio of Verrica Pharmaceuticals Inc. \u2013 DUS:1NE0", "summary": "This article focuses solely on the price-to-earnings ratio of Verrica Pharmaceuticals Inc. (DUS:1NE0), a company listed on the Dusseldorf Stock Exchange. It appears to be a stub or a data placeholder, as no specific financial figures or analyses of the ratio are provided within t", "url": "https://www.tradingview.com/symbols/DUS-1NE0/financials-statistics-and-ratios/price-earnings/", "source_name": "TradingView", "published_at": "2026-06-28T11:10:43", "published_display": "28 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Verrica Pharmaceuticals Inc. \u2013 NASDAQ:VRCA", "summary": "This article provides a financial statistic for Verrica Pharmaceuticals Inc. (NASDAQ: VRCA), specifically its enterprise value to revenue forward. The content is primarily a data point presented within the TradingView platform, with no additional textual analysis or details provi", "url": "https://www.tradingview.com/symbols/NASDAQ-VRCA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T08:10:03", "published_display": "28 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Verrica Pharmaceuticals Inc. \u2013 DUS:1NE0", "summary": "This article focuses on Verrica Pharmaceuticals Inc. (DUS:1NE0), specifically regarding its number of shareholders. It appears to be a stub or a data point from a financial platform like TradingView, indicating that specific shareholder figures are available for the company. The ", "url": "https://www.tradingview.com/symbols/DUS-1NE0/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-28T06:39:34", "published_display": "28 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Verrica Pharmaceuticals Inc. \u2013 NASDAQ:VRCA", "summary": "The article focuses on the enterprise value to EBITDA forward for Verrica Pharmaceuticals Inc. (NASDAQ: VRCA). It appears to be a financial data page rather than a detailed news article, highlighting the specific financial metric for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-VRCA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T21:10:06", "published_display": "27 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Verrica Pharmaceuticals Inc. \u2013 NASDAQ:VRCA", "summary": "This article provides financial information for Verrica Pharmaceuticals Inc. (NASDAQ: VRCA), specifically focusing on its enterprise value to EBIT forward. It presents this data within the TradingView platform context, indicating market closure and no recent trades. The content p", "url": "https://www.tradingview.com/symbols/NASDAQ-VRCA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T14:39:27", "published_display": "27 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc. Cash Flow \u2013 DUS:1NE0", "summary": "This article provides details on the cash flow of Verrica Pharmaceuticals Inc. (DUS:1NE0), listed on the Dusseldorf Stock Exchange. It highlights that the free cash flow for Q1 2026 was -7.93M EUR, and for 2025, it was -15.10M EUR with the same operating cash flow. The data cover", "url": "https://www.tradingview.com/symbols/DUS-1NE0/financials-cash-flow/", "source_name": "TradingView", "published_at": "2026-06-27T13:39:27", "published_display": "27 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Verrica Pharmaceuticals Inc. \u2013 DUS:1NE0", "summary": "This article provides financial information for Verrica Pharmaceuticals Inc. (DUS:1NE0), specifically focusing on its enterprise value to forward revenue. It indicates that no trades have occurred for the stock, and the market is currently closed. The content is primarily a data ", "url": "https://www.tradingview.com/symbols/DUS-1NE0/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T11:39:27", "published_display": "27 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRCA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Verrica Pharmaceuticals Inc. (VRCA) stock, including analyst price targets and predictions for 2027. It details recent stock performance, historical highs and lows, financial metrics like revenue and earnings, and upcoming earnings dates, alon", "url": "https://www.tradingview.com/symbols/NASDAQ-VRCA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T17:39:27", "published_display": "26 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:VRCA)", "summary": "This article provides an overview of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA), including its current stock price, market capitalization, and historical performance. It also details analyst forecasts for VRCA's future price, recent earnings, revenue figures, and upcoming earning", "url": "https://www.tradingview.com/symbols/NASDAQ-VRCA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T15:11:07", "published_display": "26 Jun 2026 15:11", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "1NE0 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Verrica Pharmaceuticals Inc. (1NE0) stock, based on analyst opinions. It includes details on the stock's highest and lowest prices, upcoming earnings reports, and financial metrics like EPS, revenue, EBITDA, and net income. Ad", "url": "https://www.tradingview.com/symbols/SWB-1NE0/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T06:39:34", "published_display": "26 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc. Actuals & Estimates (SWB:1NE0)", "summary": "This article provides an overview of Verrica Pharmaceuticals Inc.'s financial actuals and analyst estimates for the SWB:1NE0 stock. It details past earnings and revenue, future earnings report dates, stock price forecasts from analysts, and key financial metrics like EBITDA and e", "url": "https://www.tradingview.com/symbols/SWB-1NE0/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T03:09:38", "published_display": "26 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A41A98 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Verrica Pharmaceuticals Inc. (A41A98), discussing analyst ratings, recent stock performance, and financial data. It includes details on revenue, earnings, market capitalization, and upcoming earnings reports, alongside frequen", "url": "https://www.tradingview.com/symbols/LS-A41A98/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T00:41:29", "published_display": "26 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals (VRCA) Surges 6%: Momentum Builds Above Key Support - Cash Flow Strong Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNcDB0eEh5aS1HYnNVV284QWFTNXU5ZGxqdUNIVjVqMHpId29ObDBxZ2lmY1hCQ2JtTDR4RXloTzZDZXYzSmxJb2JrcGdSOXczU3lidDdqU0pqUGJmaDh0V0d0RDkwdFROUlhXaVNjeVdxSnNxQW4wSjFsU3ZQTTFXdTdMRlhXbVRiM0huampZVWF5elBmVDZlNGhtVmNaUEhZckpfWENtTXE3ZXo2VUxkRGhnazQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Alert: First US Patient Dosed in the Second Phase 3 Trial of Verrica\u2019s YCANTH for Common Warts", "summary": "Verrica Pharmaceuticals Inc. has dosed the first US patient in its second Phase 3 clinical trial (COVE-3) for YCANTH (VP-102) to treat common warts, with its Japanese partner Torii Pharmaceutical Co. also dosing the first Japanese patient. This marks a significant step towards se", "url": "https://thedermdigest.com/milestone-alert-first-us-patient-dosed-in-the-second-phase-3-trial-of-verricas-ycanth-for-common-warts/", "source_name": "The Dermatology Digest", "published_at": "2026-06-23T15:22:41", "published_display": "23 Jun 2026 15:22", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Verrica stock rating on trial progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQYzVUTlBYUmRSdzlUdTBPbTk3cVVfVHlyN0twR2JaWERNWlI5VGt0dkdCbVVXeEdoUGZLMDRuN2ZqVkVfYkhGY3ZpR0sxbUIyX2ZUNkl3cmlETVpDUmlScDBwOUk5ckhZVllfeU9EaFZHQlVtNHVLWUVXMzFXZGxWWUE2NnpscEQ4YXR2MUI4YzkyRUZwdFhrbDZXTWhOS1BSNTR2bjZqRURlXzRZYW9UbFFPejQtWWh2RFlrZ1FXZ3c?oc=5", "source_name": "Investing.com", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals (VRCA) Advances 3.19% as Stock Approaches Resistance at $6.11 - Earnings Miss Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQa3k3aFRpNHBLMFFfNDZiMERzYU9Kd0liS2tLUGZpMFNnUUVkYk9RWE9CTDEtQ2gwNkJsRmcyUDF5dEVyd215eDRPWlpzdzd6U3l3X1FoTjFGZmwwTUctM1NLcHNTXzRYajZKV2dNVVRXZUNoeGNlTElXcHdac0pVU0VYTnNGOFVWUl90OFdaSkNBdnFKbFZfRV94Q2p0MWtHYmYxMXJyOXkzUHBHU2VlZzZzS2JqTEFqUFNLdml2SQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals' Doses First US Patient in Phase 3 Trial Evaluating Ycanth to Treat Common Warts", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/verrica-pharmaceuticals-apos-doses-first-125039705.html", "source_name": "MT Newswires", "published_at": "2026-06-22T12:50:39+00:00", "published_display": "22 Jun 2026 12:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica starts Phase 3 common-warts trial with first U.S. patient", "summary": "Verrica Pharmaceuticals announced the dosing of the first U.S. patient in its COVE-3 Phase 3 clinical trial for YCANTH (VP-102) for the treatment of common warts. This marks the second pivotal trial in its global Phase 3 program, with its Japanese partner Torii Pharmaceutical als", "url": "https://www.stocktitan.net/news/VRCA/verrica-pharmaceuticals-announces-first-u-s-patient-dosed-in-the-bstfw6d23qk5.html", "source_name": "Stock Titan", "published_at": "2026-06-22T12:12:25", "published_display": "22 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH\u00ae (VP-102) for the Treatment of Common Warts", "summary": "Verrica Pharmaceuticals has announced that the first U.S. patient has been dosed in its COVE-3 clinical trial, the second pivotal Phase 3 study for YCANTH\u00ae (VP-102) targeting common warts. This follows the dosing of the first Japanese patient by their partner, Torii Pharmaceutica", "url": "https://sg.finance.yahoo.com/news/verrica-pharmaceuticals-announces-first-u-120500426.html", "source_name": "Market source", "published_at": "2026-06-22T12:12:25", "published_display": "22 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica doses first U.S. patient in common warts trial", "summary": "Verrica Pharmaceuticals Inc. has initiated its second Phase 3 clinical trial, COVE-3, for YCANTH (VP-102) to treat common warts, with the first U.S. patient dosed. Their Japanese partner, Torii Pharmaceutical, also dosed the first patient in Japan for the same study. YCANTH is al", "url": "https://www.investing.com/news/company-news/verrica-doses-first-us-patient-in-common-warts-trial-93CH-4752533", "source_name": "Investing.com", "published_at": "2026-06-22T12:12:25", "published_display": "22 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Announces First U.S. Patient Dosed", "summary": "Verrica Pharmaceuticals announced that the first U.S. patient has been dosed in the COVE-3 clinical trial, part of its Phase 3 program evaluating YCANTH\u00ae (VP-102) for common warts. This follows their Japanese partner, Torii Pharmaceutical, dosing the first Japanese patient last w", "url": "https://www.globenewswire.com/news-release/2026/06/22/3315264/0/en/verrica-pharmaceuticals-announces-first-u-s-patient-dosed-in-the-second-pivotal-clinical-trial-cove-3-of-its-phase-3-program-evaluating-ycanth-vp-102-for-the-treatment-of-common-wa.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T11:39:59", "published_display": "22 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc (VRCA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Verrica Pharmaceuticals Inc (VRCA) has an earnings forecast score of 8.00, placing it 55th out of 157 in the Pharmaceuticals industry. Analysts have set an average price target of $19.00, with a strong buy recommendation based on 6 analyst ratings. The company's expected revenue ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vrca/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T03:08:48", "published_display": "18 Jun 2026 03:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc (VRCA) Valuation: PE, PB & Fair Value Analysis", "summary": "Verrica Pharmaceuticals Inc (VRCA) has a current valuation score of 7.41, placing it 128th out of 157 in the Pharmaceuticals industry. The company's P/E ratio stands at -5.09, which is significantly below its recent high but above its recent low. Key valuation metrics such as P/B", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vrca/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T02:10:35", "published_display": "18 Jun 2026 02:10", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc (VRCA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey focuses on Verrica Pharmaceuticals Inc (VRCA), specifically attempting to detail its revenue breakdown by business segments and regional contributions. However, the core message of the article is that the relevant financial data for such a breakdown h", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vrca/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T23:39:27", "published_display": "17 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc (VRCA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Verrica Pharmaceuticals Inc (VRCA), noting its current price momentum score of 7.02 and its ranking within the Pharmaceuticals industry. It highlights that the stock is trading between a resistance level of 6.59 and a support level of", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vrca/technical", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:15", "published_display": "17 Jun 2026 20:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/verrica-pharmaceuticals-participate-jefferies-global-120500643.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T12:05:00+00:00", "published_display": "28 May 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Verrica Pharmaceuticals (VRCA) Returns To Larger Q1 Loss Challenging Bullish Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ", "summary": "", "url": "https://finance.yahoo.com/news/verrica-pharmaceuticals-participate-h-c-120000408.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T12:00:00+00:00", "published_display": "13 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call", "summary": "", "url": "https://finance.yahoo.com/news/transcript-verrica-pharmaceuticals-q1-2026-091644016.html", "source_name": "Benzinga", "published_at": "2026-05-13T09:16:44+00:00", "published_display": "13 May 2026 09:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...", "summary": "", "url": "https://finance.yahoo.com/news/verrica-pharmaceuticals-inc-vrca-q1-050137147.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T05:01:37+00:00", "published_display": "13 May 2026 05:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/917baf3d-e8b5-3075-a4f2-ff192d9b95d2/verrica-pharmaceuticals-q1.html", "source_name": "MarketBeat", "published_at": "2026-05-13T03:07:44+00:00", "published_display": "13 May 2026 03:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://finance.yahoo.com/news/verrica-pharmaceuticals-inc-vrca-reports-211502249.html", "source_name": "Zacks", "published_at": "2026-05-12T21:15:02+00:00", "published_display": "12 May 2026 21:15", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOZlZ3QUlBVzd5clhFTWdaNTNjMC1fZVNZNDF0YnRyREJOVDZlX0hEMVhoVi1mdWxDWEJHRll6YkxWNVl3X2VndVdQY1h4V0JzOHN6Y3NNUkJUbF9nbFJBdmpZV0VkWE1NQjZydVZGTUpaUVJVQUoxN1llLW5jWFR2ZkMzMzhCMTdsR21mdll6UGk0M0hLeHIyMGlUUzhyLXNUZ3VSRnFya0N5ZXh5TmpyN3lzZUdtRUdPMXM1bXJDTDdUZ25vaU03RkRlaXZpYnBpNy1NbE03dw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Verrica schedules May 12 webcast for Q1 results and update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNY1o3eEo1NHgzVmxfQ2lxRjlSbjRJU3VTNWJTTlE3TDNQRWlZeHdVbDc3bzJhMlhuX2pMSTFPc2VTM0oxSDFLNTdLd0tDaU92cmpiRzJKNkFYTDgxbi1GaUExOVFJcnBYTWFiak00RVNhTjlnRVVzdXVKSFJsbnB3TkJQVzJhakM2bkhscDlnWnhDRlNISWVHeFZ0azZjejRUVnhzLWFMVkplRHBRQzc3VFJrQ3IyN1hj?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AJBVV95cUxPUE8yWFJuSV9jUjRsY1hvaWFtTVNURmNSeHN6bldGMnRTbmNsYUFtdHRtTzFCNURKNzRQT0EwYkVxcW1hODhoNkpWVld2MDBJYmdweWR2RDNLVTlxSDc2NTRia1lTNDRKeHQzWXQwU0prSFhsMFlydDItdGl2elBUZmZtSFZsd2g1bGRQSWdhbWZxY0l2MWlIUEQtVWFPTkNyYVVMZUl1djM2Yi1LT0l5U3VQSUhleHZnSGVXd3lkV3hFTzBMdkZIZzZuUnBBaTZOYlJtM19RcWYwWTdZY051MzRDS3FMeEh5WlRGdFN4Y1FfT19KeGJXN2JfN3FveW02eXBPOHk4ZU92MzBnSE5CQnp6WFlRbXYxSXhCOWpsNjZNdHB5VWhpTXptSUxtWWh5OFRPTHNELUZTT3pQdC1hejktR2JudUJvSTZvLWVDMFFMNU5FQzFSN3ExYm9VcXFHLW9jVl94SjljZUpF?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQVXJhTGNHZnptb1h2QkYtYldWaWcxeFdIb1NZaXNqekNrM3ZsYldFSUQ5MDRoWGpsRHBnSUNuT3pWMlNTVWN5VUFQeF8tSG5OVEttdDdTTnpCb2NYd2t6RGczTFY3bUJid25Fa3pGRlJ5bEdlRlZiMkZ0X0VmWXlpLVZsV2hqbXdHMUNwS3ZuaFNDWDN4cGhTSjIzWjNIMFlEa1dRaFpDcENxMUpHUV95WFRialZIdW8?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. \u2013 VRCA", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxOUzdpLXpka1FSc3VnbEp3NWVWU08xcEFxQzRpaHdKbERmd3Jub1JzSWI3OVVzY1lQQWFBYkZxU2dIY1E3NVpiSjhkN2NQU0oxOWZzWTdLZ2V1cGl3ZGlrM1FvVDJOTWZGNXJ0UXpMYXJtNVBHRG9IQ3VzODB1Y2dzZjR4ZjFIem15bHA0RW1pYWU4dzhVS196ZFI4S1QxMjA4SVA5Q05JUzZ1VkNIZVdqVjFoc0xIOW94WU10d2RMbHVETEl2d0F6MjdsQXU1ZVZTdDREd0lSaXktVHVoMUp4dFJBU0hrYjR4ckMwVk1FVm5OWnFfX21iLWhOcUxhTl9OWlI3WG5pbTdGSXgwcWkyNWU2c0lkZ29KZmNZVk80LXZzcUt3SmtkQzl4R05wVEdqNGZqemtlTXJCR1I2UlNBNktCQlNHMGxTYl9tLTN0ZmZzdw?oc=5", "source_name": "Business Wire", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Verrica Pharmaceuticals Signs Distribution Deal With Medomie for Molluscum Treatment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/verrica-pharmaceuticals-signs-distribution-deal-124247885.html", "source_name": "MT Newswires", "published_at": "2026-07-21T12:42:47+00:00", "published_display": "21 Jul 2026 12:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica grants Medomie exclusive rights for YCANTH in Israel By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOalE0dE9PVzJndkpDeEFKS1NOd1hiX3l5WEpRMWtaRVVwVVFvd1RuS2hqUElLZDNoa2NhSUgxbmgwcjZqS1dnTGJXbG5ncUZFRWphYm1ldldNSHRySUVZS2VsNnRYNW1CcHI2Q0s1SHFmdjQxSy1vUFg5NV9FVzFnMzhCUjhjT1BlRFlwamQzakVuSkFmMTA1U1l5UURPWVRCR2dHd0pqUFpfcFBtVHd3SHExVmh1azdiTlFUTkxn?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-21T12:15:51+00:00", "published_display": "21 Jul 2026 12:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica deal could bring YCANTH to Israeli children if approved", "summary": "Verrica Pharmaceuticals has signed an exclusive distribution, marketing, and supply agreement with Medomie Pharma to commercialize YCANTH for molluscum contagiosum in Israel. While Medomie will seek regulatory approval and distribute the product, Verrica will manufacture and supp", "url": "https://www.stocktitan.net/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-emk3bsvgo9zm.html", "source_name": "Stock Titan", "published_at": "2026-07-21T11:40:50", "published_display": "21 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 92, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH\u00ae for the Treatment of Molluscum Contagiosum in Israel", "summary": "Verrica Pharmaceuticals and Medomie Pharma have entered an exclusive distribution, marketing, and supply agreement to commercialize YCANTH\u00ae for molluscum contagiosum in Israel. Medomie will seek regulatory approval and distribute the product, while Verrica manufactures YCANTH and", "url": "https://www.manilatimes.net/2026/07/21/tmt-newswire/globenewswire/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-marketing-and-supply-agreement-to-commercialize-ycanth-for-the-treatment-of-molluscum-contagiosum-in-israel/2388404", "source_name": "The Manila Times", "published_at": "2026-07-21T11:40:50", "published_display": "21 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals (VRCA) Slides 4.13% as Resistance Holds Firm - Force Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPc2x3UDRDOUoxTGV2dTVfRFhVSEJNNE5uYlV5VU0yTWVQM1BYSFpsSTNQeHRXTnFhdGtaTVYxVm1FSk1Cb0Q2RUFETG1kSVVsRGNJMVpGNER0YWVmMkdDVUxQVVpsTWFtWGpucUNXYXlHRWloTjNOdW1Gd21nc094VmlBT0thMU8yMGZFQzlNSk8wUkd1X1pObTczSk12SXR5UHRBT3JvNHdab21Udnc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-11T07:00:00+00:00", "published_display": "11 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Slips 1.68% as Stock Tests Key Support Zone - Covered Call ETF", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPTEREZElhTFU3UGx2eUd4elhOZnl4Q3NaMjF0ZXFqdG5NQzI5OS1kS1Q1Ql9PSkxpQWZ5RXFRc1dYMlpBZ3JoVm5fZ1FSVTRDZERwWWFBY2thR0QxeERWNlo2Z3NIdC1IT3Y3Q0t1M1hraHBfSEFkMHI1b0U0bDFuM0ZjUnhwNi11V01MOUJXaXZ4R05DQ2VlbENNU1BXa0RjazI4TzRiOXRWYkU?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-10T16:41:06+00:00", "published_display": "10 Jul 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals (VRCA) Q1 2026 Earnings: EPS Miss Weighs on Shares Amid Ongoing Product Launch - Fiscal Year Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxObUVXU3NJdFJHYTNDazByejdtRmduOTVoNnpVR1NmWjMyeHdlX0xlYml0cW5BMC1VS0xXVk90eUliOUVnYzhKZUVYYzl6b2d5YzVaTXBxcjBEWFlqOEozTWdMRGZaclBGZkRoRzZYQUZoZXVESnZDUl8zb2NIT0VTQ3FWRlFEb0pjWGxWTG5kSURGc2FmelNjQ1AzMEpUa0s2eEZ5N2U0RzFZYjA4R080cXg1SVdNRDJyUEM3Zldhelp6QzhFRW5RazFVU09zX1lCTzNhQ0dJSGthaGdz?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-10T05:48:20+00:00", "published_display": "10 Jul 2026 05:48", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals holds the spotlight after recent market context", "summary": "Verrica Pharmaceuticals (VRCA) is highlighted for its Nasdaq listing and SEC reporting, with its commercial product YCANTH, a prescription treatment for molluscum contagiosum, being its primary revenue driver. Investors are encouraged to focus on the company's filings, investor m", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/verrica-pharmaceuticals-holds-the-spotlight-after-recent-market-context/69716519", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T18:10:34", "published_display": "07 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript", "summary": "Verrica Pharmaceuticals Inc. reported a 25.4% increase in U.S. Ycanth product revenue for Q1 2026, alongside the launch of Wycanth in Japan, signifying global expansion. The company is actively progressing its Phase III common warts program and achieved a strong gross product mar", "url": "https://www.gurufocus.com/stock/STU:1NE0/transcripts/8853242", "source_name": "GuruFocus", "published_at": "2026-07-05T09:11:56", "published_display": "05 Jul 2026 09:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRCA - Verrica Pharmaceuticals Inc Latest SEC Filings", "summary": "This article provides detailed financial and stock performance data for Verrica Pharmaceuticals Inc. (VRCA), including its latest market capitalization, income, sales, insider ownership, institutional ownership, and various profitability and growth metrics. It also lists the comp", "url": "https://finviz.com/stock?t=VRCA&p=d&b=2&ty=lf&page=17", "source_name": "Finviz", "published_at": "2026-07-04T09:09:38", "published_display": "04 Jul 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals (VRCA) Rises 2% as Shares Test Resistance Near $6.36 - Sentiment Shift", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQVGVzNU5lX1pZTmM2MUVCTVZOejMycnBkWUxhdS1iY2JmWXlOakRCSFZha1E5cDV1X1p6NnJHZVZobnJIeEVrZVBYZGsxdUNSRXZaNXRyeXFwVjdOdUdPdFFMcVVrZmpMdzVkRFVCMzN3SG5lWHpqNkwtX0g2SkN3SFF1aUtaOXBqSFE1V1ZSNVBuMWJBeE5VdG1nd2tQZFE3V1drQnh4NWFWMENwc2Z0Z2VJNA?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc.(NasdaqCM:VRCA) added to Russell Microcap Growth Benchmark Index", "summary": "Verrica Pharmaceuticals Inc. (NasdaqCM: VRCA) has been added to the Russell Microcap Growth Benchmark Index, which is based on Friday's closing market values. This inclusion indicates the company's strong growth potential and increased visibility within the financial markets. The", "url": "https://www.marketscreener.com/news/verrica-pharmaceuticals-inc-nasdaqcm-vrca-added-to-russell-microcap-growth-benchmark-index-ce7f5fddd981f126", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:39:29", "published_display": "29 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc.(NasdaqCM:VRCA) added to Russell 3000E Growth Benchmark", "summary": "Verrica Pharmaceuticals Inc. (NasdaqCM:VRCA) has been added to the Russell 3000E Growth Benchmark. The company specializes in dermatology therapeutics, developing and selling medications for skin diseases, with its commercial product YCANTH (VP-102) for molluscum contagiosum and ", "url": "https://www.marketscreener.com/news/verrica-pharmaceuticals-inc-nasdaqcm-vrca-added-to-russell-3000e-growth-benchmark-ce7f5fdedc80f426", "source_name": "marketscreener.com", "published_at": "2026-06-29T08:41:18", "published_display": "29 Jun 2026 08:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc.(NasdaqCM: VRCA) added to Russell Microcap Index", "summary": "Verrica Pharmaceuticals Inc. (NasdaqCM: VRCA) has been added to the Russell Microcap Index. The company is a dermatology therapeutics firm focused on developing and selling medications for skin diseases, with its primary product YCANTH (VP-102) approved for molluscum contagiosum ", "url": "https://www.marketscreener.com/news/verrica-pharmaceuticals-inc-nasdaqcm-vrca-added-to-russell-microcap-index-ce7f5fdeda80f120", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:39:34", "published_display": "29 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings ratio of Verrica Pharmaceuticals Inc. \u2013 DUS:1NE0", "summary": "This article focuses solely on the price-to-earnings ratio of Verrica Pharmaceuticals Inc. (DUS:1NE0), a company listed on the Dusseldorf Stock Exchange. It appears to be a stub or a data placeholder, as no specific financial figures or analyses of the ratio are provided within t", "url": "https://www.tradingview.com/symbols/DUS-1NE0/financials-statistics-and-ratios/price-earnings/", "source_name": "TradingView", "published_at": "2026-06-28T11:10:43", "published_display": "28 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Verrica Pharmaceuticals Inc. \u2013 NASDAQ:VRCA", "summary": "This article provides a financial statistic for Verrica Pharmaceuticals Inc. (NASDAQ: VRCA), specifically its enterprise value to revenue forward. The content is primarily a data point presented within the TradingView platform, with no additional textual analysis or details provi", "url": "https://www.tradingview.com/symbols/NASDAQ-VRCA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T08:10:03", "published_display": "28 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Verrica Pharmaceuticals Inc. \u2013 DUS:1NE0", "summary": "This article focuses on Verrica Pharmaceuticals Inc. (DUS:1NE0), specifically regarding its number of shareholders. It appears to be a stub or a data point from a financial platform like TradingView, indicating that specific shareholder figures are available for the company. The ", "url": "https://www.tradingview.com/symbols/DUS-1NE0/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-28T06:39:34", "published_display": "28 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Verrica Pharmaceuticals Inc. \u2013 NASDAQ:VRCA", "summary": "The article focuses on the enterprise value to EBITDA forward for Verrica Pharmaceuticals Inc. (NASDAQ: VRCA). It appears to be a financial data page rather than a detailed news article, highlighting the specific financial metric for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-VRCA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T21:10:06", "published_display": "27 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Verrica Pharmaceuticals Inc. \u2013 NASDAQ:VRCA", "summary": "This article provides financial information for Verrica Pharmaceuticals Inc. (NASDAQ: VRCA), specifically focusing on its enterprise value to EBIT forward. It presents this data within the TradingView platform context, indicating market closure and no recent trades. The content p", "url": "https://www.tradingview.com/symbols/NASDAQ-VRCA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T14:39:27", "published_display": "27 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc. Cash Flow \u2013 DUS:1NE0", "summary": "This article provides details on the cash flow of Verrica Pharmaceuticals Inc. (DUS:1NE0), listed on the Dusseldorf Stock Exchange. It highlights that the free cash flow for Q1 2026 was -7.93M EUR, and for 2025, it was -15.10M EUR with the same operating cash flow. The data cover", "url": "https://www.tradingview.com/symbols/DUS-1NE0/financials-cash-flow/", "source_name": "TradingView", "published_at": "2026-06-27T13:39:27", "published_display": "27 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Verrica Pharmaceuticals Inc. \u2013 DUS:1NE0", "summary": "This article provides financial information for Verrica Pharmaceuticals Inc. (DUS:1NE0), specifically focusing on its enterprise value to forward revenue. It indicates that no trades have occurred for the stock, and the market is currently closed. The content is primarily a data ", "url": "https://www.tradingview.com/symbols/DUS-1NE0/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T11:39:27", "published_display": "27 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRCA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Verrica Pharmaceuticals Inc. (VRCA) stock, including analyst price targets and predictions for 2027. It details recent stock performance, historical highs and lows, financial metrics like revenue and earnings, and upcoming earnings dates, alon", "url": "https://www.tradingview.com/symbols/NASDAQ-VRCA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T17:39:27", "published_display": "26 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:VRCA)", "summary": "This article provides an overview of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA), including its current stock price, market capitalization, and historical performance. It also details analyst forecasts for VRCA's future price, recent earnings, revenue figures, and upcoming earning", "url": "https://www.tradingview.com/symbols/NASDAQ-VRCA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T15:11:07", "published_display": "26 Jun 2026 15:11", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "1NE0 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Verrica Pharmaceuticals Inc. (1NE0) stock, based on analyst opinions. It includes details on the stock's highest and lowest prices, upcoming earnings reports, and financial metrics like EPS, revenue, EBITDA, and net income. Ad", "url": "https://www.tradingview.com/symbols/SWB-1NE0/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T06:39:34", "published_display": "26 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc. Actuals & Estimates (SWB:1NE0)", "summary": "This article provides an overview of Verrica Pharmaceuticals Inc.'s financial actuals and analyst estimates for the SWB:1NE0 stock. It details past earnings and revenue, future earnings report dates, stock price forecasts from analysts, and key financial metrics like EBITDA and e", "url": "https://www.tradingview.com/symbols/SWB-1NE0/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T03:09:38", "published_display": "26 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A41A98 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Verrica Pharmaceuticals Inc. (A41A98), discussing analyst ratings, recent stock performance, and financial data. It includes details on revenue, earnings, market capitalization, and upcoming earnings reports, alongside frequen", "url": "https://www.tradingview.com/symbols/LS-A41A98/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T00:41:29", "published_display": "26 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals (VRCA) Surges 6%: Momentum Builds Above Key Support - Cash Flow Strong Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNcDB0eEh5aS1HYnNVV284QWFTNXU5ZGxqdUNIVjVqMHpId29ObDBxZ2lmY1hCQ2JtTDR4RXloTzZDZXYzSmxJb2JrcGdSOXczU3lidDdqU0pqUGJmaDh0V0d0RDkwdFROUlhXaVNjeVdxSnNxQW4wSjFsU3ZQTTFXdTdMRlhXbVRiM0huampZVWF5elBmVDZlNGhtVmNaUEhZckpfWENtTXE3ZXo2VUxkRGhnazQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Milestone Alert: First US Patient Dosed in the Second Phase 3 Trial of Verrica\u2019s YCANTH for Common Warts", "summary": "Verrica Pharmaceuticals Inc. has dosed the first US patient in its second Phase 3 clinical trial (COVE-3) for YCANTH (VP-102) to treat common warts, with its Japanese partner Torii Pharmaceutical Co. also dosing the first Japanese patient. This marks a significant step towards se", "url": "https://thedermdigest.com/milestone-alert-first-us-patient-dosed-in-the-second-phase-3-trial-of-verricas-ycanth-for-common-warts/", "source_name": "The Dermatology Digest", "published_at": "2026-06-23T15:22:41", "published_display": "23 Jun 2026 15:22", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Verrica stock rating on trial progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQYzVUTlBYUmRSdzlUdTBPbTk3cVVfVHlyN0twR2JaWERNWlI5VGt0dkdCbVVXeEdoUGZLMDRuN2ZqVkVfYkhGY3ZpR0sxbUIyX2ZUNkl3cmlETVpDUmlScDBwOUk5ckhZVllfeU9EaFZHQlVtNHVLWUVXMzFXZGxWWUE2NnpscEQ4YXR2MUI4YzkyRUZwdFhrbDZXTWhOS1BSNTR2bjZqRURlXzRZYW9UbFFPejQtWWh2RFlrZ1FXZ3c?oc=5", "source_name": "Investing.com", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals (VRCA) Advances 3.19% as Stock Approaches Resistance at $6.11 - Earnings Miss Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQa3k3aFRpNHBLMFFfNDZiMERzYU9Kd0liS2tLUGZpMFNnUUVkYk9RWE9CTDEtQ2gwNkJsRmcyUDF5dEVyd215eDRPWlpzdzd6U3l3X1FoTjFGZmwwTUctM1NLcHNTXzRYajZKV2dNVVRXZUNoeGNlTElXcHdac0pVU0VYTnNGOFVWUl90OFdaSkNBdnFKbFZfRV94Q2p0MWtHYmYxMXJyOXkzUHBHU2VlZzZzS2JqTEFqUFNLdml2SQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals' Doses First US Patient in Phase 3 Trial Evaluating Ycanth to Treat Common Warts", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/verrica-pharmaceuticals-apos-doses-first-125039705.html", "source_name": "MT Newswires", "published_at": "2026-06-22T12:50:39+00:00", "published_display": "22 Jun 2026 12:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica starts Phase 3 common-warts trial with first U.S. patient", "summary": "Verrica Pharmaceuticals announced the dosing of the first U.S. patient in its COVE-3 Phase 3 clinical trial for YCANTH (VP-102) for the treatment of common warts. This marks the second pivotal trial in its global Phase 3 program, with its Japanese partner Torii Pharmaceutical als", "url": "https://www.stocktitan.net/news/VRCA/verrica-pharmaceuticals-announces-first-u-s-patient-dosed-in-the-bstfw6d23qk5.html", "source_name": "Stock Titan", "published_at": "2026-06-22T12:12:25", "published_display": "22 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH\u00ae (VP-102) for the Treatment of Common Warts", "summary": "Verrica Pharmaceuticals has announced that the first U.S. patient has been dosed in its COVE-3 clinical trial, the second pivotal Phase 3 study for YCANTH\u00ae (VP-102) targeting common warts. This follows the dosing of the first Japanese patient by their partner, Torii Pharmaceutica", "url": "https://sg.finance.yahoo.com/news/verrica-pharmaceuticals-announces-first-u-120500426.html", "source_name": "Market source", "published_at": "2026-06-22T12:12:25", "published_display": "22 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica doses first U.S. patient in common warts trial", "summary": "Verrica Pharmaceuticals Inc. has initiated its second Phase 3 clinical trial, COVE-3, for YCANTH (VP-102) to treat common warts, with the first U.S. patient dosed. Their Japanese partner, Torii Pharmaceutical, also dosed the first patient in Japan for the same study. YCANTH is al", "url": "https://www.investing.com/news/company-news/verrica-doses-first-us-patient-in-common-warts-trial-93CH-4752533", "source_name": "Investing.com", "published_at": "2026-06-22T12:12:25", "published_display": "22 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Announces First U.S. Patient Dosed", "summary": "Verrica Pharmaceuticals announced that the first U.S. patient has been dosed in the COVE-3 clinical trial, part of its Phase 3 program evaluating YCANTH\u00ae (VP-102) for common warts. This follows their Japanese partner, Torii Pharmaceutical, dosing the first Japanese patient last w", "url": "https://www.globenewswire.com/news-release/2026/06/22/3315264/0/en/verrica-pharmaceuticals-announces-first-u-s-patient-dosed-in-the-second-pivotal-clinical-trial-cove-3-of-its-phase-3-program-evaluating-ycanth-vp-102-for-the-treatment-of-common-wa.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T11:39:59", "published_display": "22 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc (VRCA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Verrica Pharmaceuticals Inc (VRCA) has an earnings forecast score of 8.00, placing it 55th out of 157 in the Pharmaceuticals industry. Analysts have set an average price target of $19.00, with a strong buy recommendation based on 6 analyst ratings. The company's expected revenue ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vrca/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T03:08:48", "published_display": "18 Jun 2026 03:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc (VRCA) Valuation: PE, PB & Fair Value Analysis", "summary": "Verrica Pharmaceuticals Inc (VRCA) has a current valuation score of 7.41, placing it 128th out of 157 in the Pharmaceuticals industry. The company's P/E ratio stands at -5.09, which is significantly below its recent high but above its recent low. Key valuation metrics such as P/B", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vrca/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T02:10:35", "published_display": "18 Jun 2026 02:10", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc (VRCA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey focuses on Verrica Pharmaceuticals Inc (VRCA), specifically attempting to detail its revenue breakdown by business segments and regional contributions. However, the core message of the article is that the relevant financial data for such a breakdown h", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vrca/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T23:39:27", "published_display": "17 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc (VRCA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Verrica Pharmaceuticals Inc (VRCA), noting its current price momentum score of 7.02 and its ranking within the Pharmaceuticals industry. It highlights that the stock is trading between a resistance level of 6.59 and a support level of", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vrca/technical", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:15", "published_display": "17 Jun 2026 20:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/verrica-pharmaceuticals-participate-jefferies-global-120500643.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T12:05:00+00:00", "published_display": "28 May 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals (VRCA) Returns To Larger Q1 Loss Challenging Bullish Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ", "summary": "", "url": "https://finance.yahoo.com/news/verrica-pharmaceuticals-participate-h-c-120000408.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T12:00:00+00:00", "published_display": "13 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call", "summary": "", "url": "https://finance.yahoo.com/news/transcript-verrica-pharmaceuticals-q1-2026-091644016.html", "source_name": "Benzinga", "published_at": "2026-05-13T09:16:44+00:00", "published_display": "13 May 2026 09:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...", "summary": "", "url": "https://finance.yahoo.com/news/verrica-pharmaceuticals-inc-vrca-q1-050137147.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T05:01:37+00:00", "published_display": "13 May 2026 05:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/917baf3d-e8b5-3075-a4f2-ff192d9b95d2/verrica-pharmaceuticals-q1.html", "source_name": "MarketBeat", "published_at": "2026-05-13T03:07:44+00:00", "published_display": "13 May 2026 03:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://finance.yahoo.com/news/verrica-pharmaceuticals-inc-vrca-reports-211502249.html", "source_name": "Zacks", "published_at": "2026-05-12T21:15:02+00:00", "published_display": "12 May 2026 21:15", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOZlZ3QUlBVzd5clhFTWdaNTNjMC1fZVNZNDF0YnRyREJOVDZlX0hEMVhoVi1mdWxDWEJHRll6YkxWNVl3X2VndVdQY1h4V0JzOHN6Y3NNUkJUbF9nbFJBdmpZV0VkWE1NQjZydVZGTUpaUVJVQUoxN1llLW5jWFR2ZkMzMzhCMTdsR21mdll6UGk0M0hLeHIyMGlUUzhyLXNUZ3VSRnFya0N5ZXh5TmpyN3lzZUdtRUdPMXM1bXJDTDdUZ25vaU03RkRlaXZpYnBpNy1NbE03dw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica schedules May 12 webcast for Q1 results and update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNY1o3eEo1NHgzVmxfQ2lxRjlSbjRJU3VTNWJTTlE3TDNQRWlZeHdVbDc3bzJhMlhuX2pMSTFPc2VTM0oxSDFLNTdLd0tDaU92cmpiRzJKNkFYTDgxbi1GaUExOVFJcnBYTWFiak00RVNhTjlnRVVzdXVKSFJsbnB3TkJQVzJhakM2bkhscDlnWnhDRlNISWVHeFZ0azZjejRUVnhzLWFMVkplRHBRQzc3VFJrQ3IyN1hj?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AJBVV95cUxPUE8yWFJuSV9jUjRsY1hvaWFtTVNURmNSeHN6bldGMnRTbmNsYUFtdHRtTzFCNURKNzRQT0EwYkVxcW1hODhoNkpWVld2MDBJYmdweWR2RDNLVTlxSDc2NTRia1lTNDRKeHQzWXQwU0prSFhsMFlydDItdGl2elBUZmZtSFZsd2g1bGRQSWdhbWZxY0l2MWlIUEQtVWFPTkNyYVVMZUl1djM2Yi1LT0l5U3VQSUhleHZnSGVXd3lkV3hFTzBMdkZIZzZuUnBBaTZOYlJtM19RcWYwWTdZY051MzRDS3FMeEh5WlRGdFN4Y1FfT19KeGJXN2JfN3FveW02eXBPOHk4ZU92MzBnSE5CQnp6WFlRbXYxSXhCOWpsNjZNdHB5VWhpTXptSUxtWWh5OFRPTHNELUZTT3pQdC1hejktR2JudUJvSTZvLWVDMFFMNU5FQzFSN3ExYm9VcXFHLW9jVl94SjljZUpF?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQVXJhTGNHZnptb1h2QkYtYldWaWcxeFdIb1NZaXNqekNrM3ZsYldFSUQ5MDRoWGpsRHBnSUNuT3pWMlNTVWN5VUFQeF8tSG5OVEttdDdTTnpCb2NYd2t6RGczTFY3bUJid25Fa3pGRlJ5bEdlRlZiMkZ0X0VmWXlpLVZsV2hqbXdHMUNwS3ZuaFNDWDN4cGhTSjIzWjNIMFlEa1dRaFpDcENxMUpHUV95WFRialZIdW8?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. \u2013 VRCA", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxOUzdpLXpka1FSc3VnbEp3NWVWU08xcEFxQzRpaHdKbERmd3Jub1JzSWI3OVVzY1lQQWFBYkZxU2dIY1E3NVpiSjhkN2NQU0oxOWZzWTdLZ2V1cGl3ZGlrM1FvVDJOTWZGNXJ0UXpMYXJtNVBHRG9IQ3VzODB1Y2dzZjR4ZjFIem15bHA0RW1pYWU4dzhVS196ZFI4S1QxMjA4SVA5Q05JUzZ1VkNIZVdqVjFoc0xIOW94WU10d2RMbHVETEl2d0F6MjdsQXU1ZVZTdDREd0lSaXktVHVoMUp4dFJBU0hrYjR4ckMwVk1FVm5OWnFfX21iLWhOcUxhTl9OWlI3WG5pbTdGSXgwcWkyNWU2c0lkZ29KZmNZVk80LXZzcUt3SmtkQzl4R05wVEdqNGZqemtlTXJCR1I2UlNBNktCQlNHMGxTYl9tLTN0ZmZzdw?oc=5", "source_name": "Business Wire", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 104, "total_relevant": 68, "sentiment_summary": {"positive": 18, "negative": 7, "neutral": 43, "score": 55, "total": 68, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 16.3, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 15.61, "count": 30}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 18, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 5.59, "latest_week": "2026-07-17", "one_week_move": -10.7, "four_week_move": -0.7, "twelve_week_move": -19.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.027234, "market_dynamics_buy_signal": false, "relative_strength": -15.455133, "fair_value_gap": -77.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.562, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-10.7% over one week, -0.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 13}, {"label": "Market source", "count": 8}, {"label": "dars.gov.et", "count": 6}, {"label": "GlobeNewswire", "count": 5}, {"label": "TradingKey", "count": 4}, {"label": "Stock Titan", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "MT Newswires", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 59}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 30}, {"label": "Market update", "count": 29}, {"label": "Regulatory and legal", "count": 4}, {"label": "Balance sheet", "count": 3}, {"label": "Deals and strategy", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "59", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-10.7% over one week, -0.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Verrica Pharmaceuticals Signs Distribution Deal With Medomie for Molluscum Treatment"}], "updated_at": "2026-07-22T01:10:39.798656+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}